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Antibiotic resistance is one of the main public health problems worldwide, reducing 
treatment options and increasing morbidity and mortality.  The production of extended-
spectrum β-lactamases (ESBLs), plasmid mediated (pAmpC) β-lactamases are the most 
important resistance mechanisms that hamper antimicrobial treatment of infections 
caused by Enterobacteriaceae. This study describes the detection and characterization of 
pAmpC- and/or ESBL-producing clinical isolates of Escherichia coli (n=230) from 
urine and blood samples at the Central Hospital of Maputo, Mozambique from mid-
August to mid-November 2015. Antimicrobial susceptibility testing was performed by 
the disc diffusion method. Isolates with reduced susceptibility to cefotaxime and/ or 
ceftazidime (n=75) were subjected to phenotypic AmpC- and/or ESBL testing as well as 
PCR-detection of blaCTX-M, blaTEM, blaSHV, blaCMY, blaMOX, blaFOX and blaDHA. A total 
of 75/230 (32.6 %) isolates were ESBL positive, and twenty-five of these were pAmpC 
positive. The most prevalent ESBL and pAmpC were CTX-M (77%) and FOX (32%), 
respectively. Most CTX-M negative ESBL-strains were blaSHV positive indicating a 
SHV-ESBL-type. The presence of co-resistance (R and I) to clinically important 
antibiotics were also frequent; blood ciprofloxacin (CIP; n= 12/17: 70.6%), gentamicin 
(GEN; n= 8/17: 47.1 %) and trimethoprim-sulfamethoxazole (SXT; n= 17/17; 100%) 
and urine CIP (n=40/58; 68.9%), GEN (n= 27/58; 46.5 %) and SXT (n= 55/58; 94.8%). 
Multidrug resistance was observed in 17/17 (100 %) and 58/58 (100 %) blood and 
urinary isolates, respectively. ERIC-PCR analysis revealed a large genetic diversity of 
strains with some minor clusters indicating intra hospital spread. 
The study has shown that: (i) a large proportion of clinical isolates of E. coli from the 
urinary tract and blood cultures from the Central Hospital are pAmpC and/or ESBL-
producing. (ii) CTX-Ms and FOX were the dominant ESBL- and pAmpC-types, 
respectively. (iii) All ESBL- and pAmpC-producing strains were MDR-strains only 
susceptible to antibiotics that are not easily available in the current location. The overall 
findings strongly support the urgent need for strengthened and rapid diagnostic services 
to guide correct treatment of serious life-threatening infections and improved infection 
control measurements. 
Key words: E.coli; antibiotic resistance; extended-spectrum β-lactamase (ESBL); 
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1 INTRODUCTION 
Antimicrobial resistance (AMR) is a global public health threat making commonly used 
antibiotics inefficient in the treatment of infectious diseases (WHO 2015). Beta-lactam 
have since the 1940s been our most successful antibiotics in the treatment of various 
bacterial infections. The global expansion of different resistance mechanisms towards 
beta-lactams are observed in both Gram-positive and Gram-negative bacteria. 
 
 The production of β-lactamases is the most common mechanism of bacterial resistance 
to β- lactam antibiotics in Gram-negative bacteria. Beta-lactamases are a large group of 
enzymes that are capable of hydrolyzing the beta-lactam ring of beta-lactam antibiotics.  
β- lactamase genes are widespread and mutate in response to continuous antibiotic 
exposure [Nkrumah et al., 2013]. The production of extended-spectrum β-lactamase 
(ESBLs), plasmid-mediated AmpC (pAmpC) enzymes and carbapenemases are the 
most important resistance mechanisms that hamper the antimicrobial treatment of 
infections caused by Enterobacteriaceae [Paterson and Bonomo 2005].  
 
Eschericia coli and Klebsiella pneumoniae are amongst the most commonly 
encountered bacteria producing ESBLs, pAmpC and carbapenemases, but nowadays 
detection of these enzymes has also been observed in several other species of 
Enterobacteriaceae and Pseudomonas species [Paterson 2014]. 
 
The first description of K. pneumoniae and E. coli resistant to third generation 
cephalosporins was in Germany in 1983 [Trabulsi et al., 2004]. Since then, numerous 
types of enzymes have been reported in many different countries at all continents 
[Trabulsi et al., 2004].  Moreover, the beta-lactamases are most often encoded by genes 
on mobile genetic elements that also confer other resistance mechanisms [Coque et al., 
2008]. This notion explains that ESBL strains have been associated with resistance to 
non-β-lactam antibiotics like the aminoglycosides, fluoroquinolones, trimethoprim-
sulfamethoxazole and/or chloramphenicol [Khurana  et al.,2002]. 
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1.2 LITERATURE REVIEW 
Infectious diseases continue to account for a larger percentage of the global disease 
burden, affecting more people in developing countries. Urinary tract infection (UTI) is a 
disease of high incidence in both community and nosocomial settings [Peirano et 
al.,2014]. UTIs cause significant morbidity and mortality, with approximately 150 
million cases globally per year. Uropathogenic E. coli (UPEC) is the primary cause of 
UTI and is generally treated empirically according to their predicted antibiotic 
susceptibility profile [Trabulsi et al., 2004]. This section reviews important 
characteristics of E. coli, infections caused by E. coli, beta-lactam antibiotics and their 
role in the treatment of E. coli infections, some aspects of multi drug resistant E. coli, 
and resistance mechanisms against beta- lactam antibiotics. 
1.2.1 Escherichia coli: basic characteristics and pathogenicity 
Escherichia  coli 
E. coli is one of the most extensively studied Gram-negative bacteria belonging to the 
family Enterobacteriaceae [Bang 2016, Nicolau 2008]. This species is widely dispersed 
in nature and found in soil, water and has been associated with intestinal and extra 
intestinal infections in humans and many animals. E. coli is facultative anaerobic and 
thus preferably uses aerobic respiration in oxygen containing environments [Nicolau 
2008]. 
 
E. coli contains an inner membrane, a peptidoglycan layer and an outer membrane. E. 
coli has a genome with a common backbone of genes (core genome), but among the 
different types of E. coli there is great genomic diversity [Bang 2016]. 
 
Certain strains have acquired specific virulence factor which are associated with a 
spectrum of disease. Currently, six major groups of intestinal pathogenic E. coli have 
been recognized: entero-pathogenic E. coli; Shiga toxin-producing E .coli, entero-
aggregative E. coli, entero-toxigenic E. coli, entero-invasive E. coli, and diffusely 
adherent E. coli [Tang et al., 2016]. It has been estimated that catheter-associated UTIs 
caused by E. coli represent one of the most common causes of nosocomial infection in 




E. coli can also cause diseases such as urinary tract infections, diarrhoea, hemorrhagic 
colitis and hemolytic uremic syndrome [Paterson 2014]. The number of extra intestinal 
pathogenic Escherichia coli (ExPEC) infections is increasing worldwide, leading to a 
tremendous burden on public health [Mellata 2013]. In addition to causing human 
diseases, ExPEC strains are responsible for significant economic losses in animal 
production, particularly within the poultry industry as one of the fastest growing 
industries in the United States and worldwide [Paterson and Bonomo 2005]. 
The widespread use of antimicrobials, coupled with the transmission of genetic 
elements carrying resistance determinants in the form of plasmids, transposons, and 
integrons, are major contributors to the increasing worldwide prevalence of 
antimicrobial resistance [Trang et al., 2013]. E. coli is heavily exposed to antimicrobial 
selection as a major human and animal commensal pathogen. Combined with its large 
genomic diversity including mobile genetic elements, E. coli is a significant hub for 
acquired multidrug resistance.In Africa, there is a disproportionate burden of global 
childhood mortality caused by infectious diseases. Invasive bacterial infections are 
major contributors to this excess mortality among children and Streptococcus 
pneumoniae, Staphylococcus aureus, E. coli, are the most common bacterial pathogens 
[Mandomando et al., 2010].  
Africa in general and Mozambique in particular is often limited by infrastructure, cost, 
and human resource constraints [Moon et al., 2010]. The absence of microbiologic 
capacity for diagnosis and surveillance outside the main research centres and teaching 
hospitals forces many clinicians to practice without any locally relevant data about 
distribution of pathogens, antimicrobial susceptibility patterns or their evolution in time 
[Moon et al., 2010]. 
 
1.2.2 Multi- Drug Resistant Escherichia coli 
Antimicrobial resistance hinders effective treatment of some of the leading causes of 
morbidity and mortality in the developing world. Antibiotics given empirically without 
proper antibiotic susceptibility testing are one of the major causes for the continuous 




Antibiotics most often target cell wall biosynthesis, protein synthesis or DNA 
replication and repair in bacteria [Moon et al., 2010]. Antibiotic use in the society has 
contributed to selection pressure which gives rise to antibiotic-resistant microbes.  
Therefore antibiotic stewardship, implementation of basic hygiene procedures and 
sanitations are important factors in limiting the spread of resistant microbes [Bang 
2016]. 
 
The extended-spectrum beta-lactamases (ESBLs) are class A plasmid mediated 
enzymes that hydrolyse oxyimino cephalosporin and monobactam antibiotics but are 
inhibited by clavulanic acid in vitro. E. coli harbouring ESBLs confer resistance to 
penicillin, narrow and extended-spectrum cephalosporin, and aztreonam antibiotics. 
They also frequently show up as multidrug resistant expressing co-resistance to 
commonly used important antibiotics such as aminoglycosides, 
trimethoprim/sulfamethoxazole, and quinolones [Rezai et al. 2014, Moon et al. 2010]. 
 
Thus, infections caused by ESBL-producing Enterobacteriaceae have serious 
implications for both public health and infection control practices [Nicolau 2008]. 
These infections often undermine empirical treatment regimens and cause delays in the 
administration of effective therapy [Nicolau 2008]. 
 
1.2.3. β-Lactam antibiotics, their use and mechanism of action 
The β-lactams are a broad class of antibiotics that include the penicillins, 
cephalosporins, cephamycins, monobactams and carbapenems [Tang 2016]. They have 
an important place in the therapy of Gram- negative organisms including infections 
caused by E. coli, either as mono therapy or in combination with other antibiotics [Tang 
2016]. Beta-lactams kill susceptible bacteria by specifically inhibiting the 
transpeptidases that catalyzes the final step in cell wall biosynthesis, the cross-linking of 
peptidoglycan [Yocum et al., 1980]. 
 
The introduction of penicillin, in the early 1940s, was perceived as marking the end of 
infectious diseases but penicillin resistant Staphylococcus aureus strains was reported 
just a few years after its use [Francisco et al., 2014]. Penicillin was the first of the β- 
lactam antibiotics consisting to thiazolidine ring connected to a β – lactam ring with an 
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acyl side chain. Penicillin G and penicillin V, were the first natural synthetic penicillin, 
have a little activity against Gram negative bacteria and are susceptible to hydrolysis by 
β – lactamases [Drawz and Bonomo 2010, Francisco et al., 2014].   
 
The third- generation cephalosporin have become an important tool in the treatment of 
severe infection caused by E. coli and other Enterobacteriaceae. Unfortunately the 
ESBLs are now the major mechanism behind the increasing resistance against 
penicillin, and all cephalosporins (except cephamycins) and monobactams [Coque et al., 
2008]. pAmpC β lactamases are sensitive to 4
th
 generation cephalosporins (cefepime, 
cefpirome) and carbapenems, but confer resistance to second and third cephalosporins 
as well as cephamycins. Carbapenemases have the ability to hydrolyze virtually all 
betalactam drugs [Datta et al., 2014]. 
 
Historically, the carbapenems have been reserved as last-resort agents in the treatment 
of serious or highly resistant infections as they are not compromised by ESBLs or 
pAmpCs. ESBL and AmpC enzymes generally lack the ability to hydrolyze the 
carbapenems, but reduced susceptibility or resistance to carbapenems can arise when 
such enzymes are accompanied by decreased outer membrane permeability [Datta et al., 
2014]. Importantly, b-lactamase enzymes with carbapenemase activity have now spread 
worldwide and are beginning to compromise the use of even carbapenems [Doi and 
Paterson, 2015].  
Carbapenems are stable against most β-lactamases mainly due to the structural 
modifications, such as a carbon at position C-1 and a hydroxyethyl R-2 side chain. 
Modifications in structure of the first carbapenem, thienamycin, led to the development 
of imipenem, meropenem, ertapenem and more recently, doripenem [Pérez and Hanson 
2002]. 
 
1.2.4 Mechanisms of resistance to β- Lactams 
Antibiotic-resistant bacteria are difficult to treat and can be associated with high 
morbidity and mortality. Therefore, they pose a great threat to public health. There is no 
exception for Enterobacteriaceae, and their ability to acquire resistances to broad-
spectrum beta-lactam antibiotics [Tang et al. 2016]. 
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1.2.4.1 Beta- Lactamase- Mediated Resistance 
ESBLs are enzymes capable of hydrolysing oxyimino-β-lactams, such as third 
generation cephalosporins, which include the commonly used antimicrobials, 
ceftriaxone, ceftazidime and cefotaxime. The β-lactamases are grouped into four main 
classes, namely: A, B, C and D by the Ambler classification based on their biochemical 
characteristics. Classes A, C and D are serine β-lactamases and class B enzymes are 
metallo- β-lactamase [Sonda et al., 2016].The dissemination of ESBLs is a global 
problem, particularly for K. pneumonia and E. coli [Nasser and Sundsfjord 2011]. CTX-
M-type β-lactamases are the dominant ESBL-type worldwide. CTX-Ms, which 
preferentially hydrolyze cefotaxime were first reported in the late 1980s and have since 
undergone a rapid, global spread. The spread of CTX-M-type β- lactamases has been 
dramatic and greater than the impact of the TEM- and SHV-type ESBLs [Nasser and 
Sundsfjord 2011]. 
 
Plasmid mediated AmpC β lactamases (pAmpC) are enzymes which belong to class C 
of Ambler. These enzymes confer resistance to a wide variety of β lactam drugs 
including cephamycins and β lactamase inhibitors like clavulanic acid, sulbactam and 
tazobactam to which class enzyme (ESBLs) are sensitive [Masud et al., 2014]. 
 
For a long time, carbapenems have been considered as an important antibiotic for the 
treatment of enterobacteriaceae infection. However, now carbapenem-resistant 
Enterobacteriaceae (CRE) has become a global issue. [Tang et al.  2016]. 
 
The development of resistance to carbapenems among E. coli is of particular concern 
because these agents are often the last line of effective therapy in invasive infections. 
New Delhi metallo-β-lactamase (NDM) and carbapenem-hydrolyzing class D β-
lactamases such as oxacillinase-48 (OXA-48) are the most common carbapenemases 
among E. coli worldwide. [Peirano et al., 2014, Poumaras et al., 2013]. 
Carbapenemase identified in Enterobacteriaceae, Pseudomonas aeruginosa and 
Acinetobacter baumannii are placed in three classes of β-lactamase as Ambler class A, 
class B metallo β-lactamases, and carbapenem hydrolyzing class D oxacillinases 
[Ronald et al., 2011]. Carbapenemase are classified into two major types based on the 
active site of the enzyme as serine carbapenemase (KPC- Klebsiella pneumonia 
Carbapenemase and OXA type β-lactamase) and metallo-β-lactamase (IMP- 
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Imipenemase, VIM- Verona Integron-Encoded Metallo-β-Lactamase, and NDM-New 
Dehli Metallobetalactamase). [Reich et al., 2013]  
 
1.3 RESEARCH QUESTION  
Considering that E. coli is the most common bacteria isolated in the microbiology 
laboratory of Maputo Central Hospital , it is imperative to undertake the phenotypic and 
genotypic characterization of resistance mechanisms in these E. coli using a prospective 
study with a view of informing empiric therapy and treatment guidelines. For that, we 
designed the following research question:  
 
What is the occurrence of and the phenotypic and genotypic profile of ESBL- 
and/or pAmpC-producing clinical isolates of E. coli in samples processed in the 
Microbiology Laboratory of Central Hospital of Maputo in August to November-
2015? 
 
1.3.1 AIM AND STUDY OBJECTIVES 
To delineate the occurrence of and the pheno-/genotypic characteristics of ESBL- 
and/or pAmpC-producing E. coli from the microbiology laboratory of Maputo Central 
Hospital - the study had the following objectives: 
1- Isolate and confirm the identity of clinical isolates of E. coli processed from 
urinary tract and blood culture samples at Maputo Central Hospital in a defined 
time period. 
2- Ascertain the antibiotic susceptibility of isolates against an appropriate panel of 
antibiotics by agar disc diffusion according to the CLSI method. 
3- Examine for ESBLs and/or increased AmpC-production using specific double- 
disc synergy tests in isolates with reduced susceptibility to cefotaxime and/or 
ceftazidime. 
4- Examine for carbapenemase production in isolates with reduced susceptibility to 
meropenem.  
5- To definitively identify the ESBL-, pAmpC- and carbapenemase encoding genes 
by PCR and sequencing and assess the genetic relatedness between pAmpC- 
and/or ESBL-positive strains by ERIC-PCR. 
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6- To provide these data in the process of establishing empirical antibiotic 
treatment guidelines used at Maputo Central Hospital. 
 
1.4. CHAPTER STRUCTURE 
This research is presented in the following chapters: 
Chapter 2. Manuscript intended for submission to the Journal of Infection in Developing 
Countries: Extended spectrum β-Lactamase and plasmid AmpC mediated resistance in 
clinical isolates of Escherichia coli from the Central Hospital of Maputo – Mozambique 
2015. This manuscript addresses objectives 1-6 as stated above. 
Chapter 3. Conclusion. This final chapter indicates the extent to which the objectives 
have been met, outlines limitations and recommendations, and highlights the 
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Antibiotic resistance is one of the main public health problems worldwide, reducing 
treatment options and increasing morbidity and mortality.  The production of extended-
spectrum β-lactamases (ESBLs), plasmid mediated AmpC β-lactamases (pAmpC) and 
linked co-resistances are the most important resistance mechanisms that hamper 
antimicrobial treatment of infections caused by Enterobacteriaceae. This study describes 
the detection and characterization of pAmpC- and/or ESBL-producing clinical isolates 
of Escherichia coli (n=230) from urine and blood samples at the Central Hospital of 
Maputo, Mozambique from mid-August to mid-November 2015. Antimicrobial 
susceptibility testing was performed by the disc diffusion method. Isolates with reduced 
susceptibility to cefotaxime and/ or ceftazidime (n=75) were subjected to phenotypic 
AmpC- and/or ESBL testing as well as PCR-detection of blaCTX-M, blaTEM, blaSHV, 
blaCMY, blaMOX, blaFOX and blaDHA. A total of 75/230 (32.6 %) isolates were ESBL 
positive, and twenty-five of these were pAmpC positive. The most prevalent ESBL and 
pAmpC were CTX-M (77%) and FOX (32%), respectively. Most CTX-M negative 
ESBL-strains were blaSHV positive indicating a SHV-ESBL-type. The presence of co-
resistance (R and I) to clinically important antibiotics were also frequent; blood 
ciprofloxacin (CIP; n= 12/17: 70.6%), gentamicin (GEN; n= 8/17: 47.1 %) and 
trimethoprim-sulfamethoxazole (SXT; n= 17/17; 100%) and urine CIP (n=40/58; 
68.9%), GEN (n= 27/58; 46.5 %) and SXT (n= 55/58; 94.8%). Multidrug resistance was 
observed in 17/17 (100 %) and 58/58 (100 %) blood and urinary isolates, respectively. 
ERIC-PCR analysis revealed a large genetic diversity of strains with some minor 
clusters indicating intra hospital spread. 
The study has shown: (i) a large proportion of ESBL- and/or pAmpC-producing clinical 
isolates of E. coli from the urinary tract and blood cultures from the Central Hospital 
with CTX-Ms. (ii) CTX-Ms and FOX were the dominant ESBL- and pAmpC-types, 
respectively. (iii) All ESBL- and pAmpC-producing strains were MDR-strains only 
susceptible to antibiotics that are not easily available in the current location. The overall 
findings strongly support the urgent need for strengthened and rapid diagnostic services 




Key words: E. coli; antibiotic resistance; extended-spectrum β-lactamase (ESBL); 
plasmid mediated AmpC 
Introduction 
There is an increasing awareness about the growing worldwide problem with 
antimicrobial-resistant bacteria in the community and health care facilities. Resistance 
to antimicrobial agents occurs in all parts of the world with an increasing prevalence 
and threatens human and animal health [WHO 2015]. Thus, the World Health 
Organization (WHO) now recognizes antimicrobial resistance (AMR) as one of the 
principal public health problems of the 21
st
 centuries threatening the effective 
prevention and treatment of an ever-increasing range of infections caused by bacteria, 
parasites, viruses and fungi [Prestinaci et al., 2015].  
 
The production of β-lactamases is the most common mechanism of resistance to β-
lactam antibiotics in Gram-negative bacteria. Beta-lactamases are a large group of 
enzymes that are capable of hydrolyzing the β-lactam ring of β-lactam antibiotics. β-
lactamase genes are widespread, mutate and adapt in response to continuous antibiotic 
exposure [Nkrumah et al., 2013]. 
Extended spectrum β-lactamases (ESBL) are enzymes that hydrolyse an extended 
spectrum of β-lactam antibiotics including penicillins and cephalosporins with an 
oxyimino side chain [Paterson and Bonomo 2009]. These cephalosporins include 
cefotaxime, ceftriaxone and ceftazidime as well as the oxyimino-monobactam  
aztreonam. The most widely distributed ESBLs enzymes, are CTX-M-type β-
lactamases, which preferentially hydrolyze cefotaxime. CTX-Ms were first reported in 
the late 1980s and have since undergone a rapid, global spread. The dissemination of 
CTX-M-type β- lactamases has been dramatic and greater than the impact of the TEM- 
and SHV-type ESBLs [Paterson and Bonomo 2009]. 
 
AmpC β-lactamases are also an important cause of beta- lactam resistance in Gram-
negative bacteria [Jacoby 2009]. Many Gram-negative bacteria including most 
Enterobacteriaceae have chromosomally encoded AmpC-betalactamases. Some AmpC-
genes have been mobilized from their chromosomal origin and may be spread between 
bacteria by plasmids. They are named plasmid-mediated AmpC (pAmpC), and include 
MOX, FOX, DHA and CMY, which are the most prevalent [Jacoby 2009]. AmpC-
17 
 
betalactamases confer resistance to a wide variety of β-lactam drugs including 
penicillins, 1-3 generation cephalosporins as well as  β-lactamase inhibitors like 
clavulanic acid, sulbactam and tazobactam to which class enzyme (ESBLs) are sensitive 
[Paterson 2014]. ESBLs and pAmpCs may be present together in the bacteria. The 
effect of pAmpC β-lactamase expression may phenotypically mask the presence of 
ESBLs which may result in failure to detect these enzymes [Prestinaci et al., 2015].  
Among the beta-lactamases, the emerging carbapenemases, especially transferrable 
metallo-beta-lactamases (MBLs) are of particular concern because of their ability to 
hydrolyze virtually all beta-lactams, including the carbapenems [Datta et al., 2014]. 
Escherichia coli and Klebsiella pneumoniae are amongst the most commonly 
encountered clinical isolates producing ESBLs, pAmpCs or carbapenemases, however, 
they have been observed in other species of Enterobacteriaceae, as well as 
Acinetobacter baumannii and Pseudomonas aeruginosa [Datta et al., 2014]. 
 
In the context of developing countries, there is limited data from large surveillance 
studies on antimicrobial resistance [Mandomando et al., 2010, Moon et al., 2013]. In 
addition, few clinical studies document the susceptibility pattern of common causative 
pathogens in humans; partly due to the lack of microbiological facilities in many health 
facilities [Datta et al., 2014]. This study delineates plasmid AmpC- and ESBL-mediated 
resistance in clinical isolates of E. coli routinely processed in the Maputo Central 
Hospital, Mozambique. 
Material and Methods 
Bacterial strains 
The bacterial strains were collected at Maputo Central Hospital, a 1000-bed reference 
hospital in Maputo, Mozambique. We included urine and blood culture samples 
received at the Department of Clinical Microbiology from mid-August and through 
mid-November 2015. The urine samples were obtained from both in- and outpatient 
whereas blood cultures were only from inpatients. 
  
Ethical considerations 
This study was approved by the Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal (BE 030/16) and the Institutional Bioethics Committee 




Identification and susceptibility testing 
Bacterial identification was performed using standard biochemical tests including API- 
20E kit (Biomerieux, la Balme-les-Grottes, France). Strains identified as E.coli were 
further characterized with antimicrobial susceptibility testing (AST). AST was 
performed using the Kirby-Bauer disk diffusion method according to CLSI guidelines 
[CLSI 2015]. Multidrug-resistance was defined as acquired non-susceptibility to at least 
one agent in three or more antimicrobial categories [Magiorakos et al., 2011]. 
Internal quality assurance was performed weekly during the whole study period using 
the wild type E. coli ATCC 25922 strain. In addition the K. pneumoniae ATCC 700603 
(ESBL-type SHV-18 positive) and the E.coli A5-8 (blaDHA) were used as ESBL- and 
AmpC-positive controls, respectively. The A5-8 strain was obtained from the 
Norwegian Advisory Unit for Detection of Antimicrobial Resistance. Strains were 
stored in skimmed milk broth with 10% glycerol at -70˚C until they were subjected to 
molecular analysis.  
 
Phenotypic detection of β- lactamase 
Strains that showed reduced susceptibility (I or R) to cefotaxime and/or ceftazidime 
were examined for ESBL-production. Strains with reduced susceptibility to cefotaxime 
and/or ceftazidime and cefoxitin were examined for increased AmpC-production. 
[http//www.eucast.org/fileadmin/src/med 2016]. The mechanisms of resistance were 
examined using ROSCO combined disc tablets (ROSCO Taastrup, Denmark) for 
ESBL-A, AmpC- detection and interpreted according to instructions of the 
manufacturer. 
 
Genotypic characterisation of β-lactamases 
The genetic characterization was performed at the Anitimicrobial Research Unit, 
UKZN. All isolates were screened for the presence of blaTEM, blaSHV, blaCTX-M, blaCMY, 
blaDHA, blaFOX and blaMOX genes using PCR with the specific primers given in Table 1. 
Briefly, the bacterial strains were grown on nutrient agar overnight at 35±2˚C for 16-
18h. DNA extractions were performed using GeneJet Purification kit (Thermo 
Scientific) according to the manufacturer’s instructions. The extracted DNA was stored 
at -20°C until used as DNA template for gene amplifications using PCR. 
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The PCR amplification mixture was prepared in a final volume of 25µL: 7.5µL 
sterilised distilled water; 1µL template DNA, 2µL of each primer; forward and reverse 
primers (Inqaba Biotechnology Industries, South Africa) and 12.5µL of master mix 
(Applied Biosystems, USA). Amplification were undertaken using T100
TM 
Thermal 
cycler (Bio-Rad, USA) and comprised of a preliminary denaturation at 98˚C for 10s, 
followed by denaturation at 98˚C and extension of 72˚C for 15s for 30 cycles, with a 
final extension of 72˚C for 1 min.  The same PCR conditions were used for the other 
genes but with the following annealing temperatures: TEM (56 ˚C), SHV (56 ˚C), and 
CTX-M (57 ˚C). 
The products were run on 1.5% agarose gel at 120 V for 45 min, stained with gel red 
and visualized using Bio-Rad’s ChemiDoc
TM 
MP System. CTX-M-positive PCR 
products were sent for DNA sequencing at Inqaba Biotec. 
 
Genomic profiling by ERIC-PCR 
The clonal relatedness of ESBL-positive isolates was examined by ERIC- PCR 
[Versalovic et al., 1991]. The total reaction volume was 10 µL, which contained 2µL of 
template DNA and 0.1µL primers and 5 µL of DreamTaq mastermix (Thermo 
Scientific). The primers ERIC 1 and ERIC 2 were use [Versalovic et al., 1991] PCR 
conditions were as follows: 94 °C for 3 min, 30 cycles of 30 s of denaturation at 94 °C, 
1 min of annealing at 50 °C, 8 min of extension at 65 °C and a final elongation at 16 
min at 65 °C. The ERIC-PCR products were loaded on a 1% (w/v) agarose gel. The 
products were visualized by UV transillumination (Syngene, UK) after staining in 0.1 
mg/mLgel red for 15 min. Genotypic variation were analysed using the GelComparII 
version 6.0 software package (Applied Maths) and Unweighted Pair Group Method 
with Arithmetic Mean (UPGMA) cluster analysis to produce a dendrogram. 
Results 
Strain selection and antimicrobial susceptibility testing 
Clinical samples (n=3326) were received during the study period from in-patients at 
different departments, Maputo Central Hospital (n= 1841; 55.4 %) as well as from 
outpatients (n=1485; 44.6%). A total of 1078/3326 (32.4%) samples were from urine 
(n=823; 24.7 %) and blood (n=255; 7.7 %). E. coli strains were identified from urine 
(n=199/823; 24.1%) and blood (n=31/255; 12.1%) culture samples. A total of 140/230 
(60.8%) and 90/230 (39.1%) E.coli strains were obtained from in- and outpatients, 
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respectively, including urinary strains from in- (n=109) and outpatients (n=90). All 
blood culture isolates were from inpatients. 
A total of 17/31 (55 %) blood culture and 58/199 (29 %) urine isolates showed reduced 
susceptibility (R or I) to cefotaxime and/or ceftazidime (Tables 2 nr 3). The ESBL 
confirmation test was positive for all 75/230 (32.6 %) isolates. Among the urinary 
samples (n=199) the ESBL-positive rates were 8/90 (8.8 %) and 50/109 (45.8 %) for 
out- and inpatients, respectively.  
Reduced susceptibility to meropenem was not observed. Reduced susceptibility to 
cefoxitin was observed in 41/75 (54.6 %) of the isolates and further examined for 
increased AmpC-production; 7/17 and 34/58 blood and urine strains, respectively 
(Table 2 and Table 3). A total of 25/41 (60.9 %) isolates were confirmed AmpC positive 
using the ROSCO combined disc method, representing 25/75 (33 %) of the total ESBL-
positive population. 
The presence of co-resistance (R and I) to clinically important antibiotics were also 
examined (Tables 2 and 3); blood ciprofloxacin (CIP; n= 12/17: 70.6%), gentamicin 
(GEN; n= 8/17: 47.1 %) and trimethoprim-sulfamethoxazole (SXT; n= 17/17; 100%) 
and urine CIP (n=40/58; 68.9%), GEN (n= 27/58; 46.5 %) and SXT (n= 55/58; 94.8%). 
Interestingly, most of the isolates, even pAmpC-negative, expressed resistance to 
betalactamase inhibitors (amoxicillin-clavulanic acid and piperacillin-tazobactam) 
indicating additional resistance mechanisms beyond ESBL.  
Multidrug resistance defined as acquired non-susceptibility to at least one agent in three 
or more antimicrobial categories [Magiorakos at al., 2011], was observed in 17/17 (100 
%) and 58/58 (100 %) blood and urinary isolates, respectively. 
Detection of genes encoding ESBL and plasmid-mediated AmpC.  
A total of 58/75 (77 %) and 39/75 (52 %) ESBL-positive strains scored positive for 
blaCTX-M, blaSHV and blaTEM by PCR, respectively (Fig 1). The blaCTX-M amplicons were 
sequence-typed with the following results: CTX-M 15 (n=24), CTX-M 28 (n=2), CTX-
M 117 (n=1), CTX-M 36 (n=1), CTX-M 164 (n=1) and CTX-M no typing (n=29). 
Available resources did not allow sequence typing of SHV-amplicons. But, a total of 
13/17 blaCTX-M negative ESBL-specimen were blaSHV-positive, indicating a SHV-ESBL-
type. Only one isolate was blaTEM positive, and this strain was positive for blaCTX-M 15. 
Surprisingly, a total of 25/75 (33 %) strains examined scored positive for one of more 
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plasmid mediated AmpC genes (Fig 1); blaCMY (n=1), blaDHA (n=13), bla MOX (n=22), 
and blaFOX (n=24). The strains contained two (n=15) or three (n=10) pAmpC genes: 
blaCMY;DHA (n=1); blaDHA;FOX (n=2), blaMOX;FOX (n=12)  and blaDHA;MOX;FOX (n=10). 




ERIC – PCR Results 
Distinct profiles were obtained for the 75 isolates tested using ERIC-PCR fingerprinting 
(Fig. 1). Fragments of different molecular weights were observed and polymorphisms 
based on fragment length were used as a means of differentiating E. coli isolates. The 
absence or presence of a band was also noted in determining variation among the 
isolates. ERIC-PCR profiles comprised between 4 and 12 individual bands, varying in 
size from 0.5 – 10 kb (Fig. 1).  Amplifications of different intensities were observed and 
visual analysis of the ERIC profiles included primary, secondary and tertiary 
amplification. Primary amplification products refer to those products of high intensity, 
which appear extremely bright on the gels. Secondary amplification products are those 
products that are not as bright as the primary amplification products but more intense 
that the tertiary amplification products, while the tertiary amplification products are the 
minor amplification products of low intensity.  All isolates were type able using this 
fingerprinting technique and band patterns were reproducibly obtained under repeat 
amplification. 
 
The ERIC–PCR profiles allowed the differentiation of the 75 isolates into 50 ERIC-
PCR types, which were grouped into eight main clusters (A – H), with each of the 
clusters being sub-divided into two or three main sub-clusters (Fig. 1). The urine 
isolates were diverse and distributed in all eight identified clusters (clades A-H) with 
characteristics as outlined below.  Isolates with similar profiles demonstrated different 
β-lactamase gene content. The blood isolates were more clonal in nature and mostly 
observed in clusters F and G, but predominantly in cluster G. Although closely related, 
they did demonstrate differences in their β-lactamase resistance gene content.  
 
Clade A comprised of 10 strains; urine (n=9) and blood (n=1), and CTX-M positive 
(n=8). These strains were from samples collected in patients admitted at the departments 
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of pediatrics (n=5), internal medicine (n=2) as well as outpatients (n=3). The eight 
CTX-M positive strains were from pediatrics (n=5), internal medicine (n=1) and 
outpatients (n= 2).  One strain was positive for pAmpC-genes.  Twelve strains were 
clustered in clade B; urine (n=11) and blood (n= 1).  The strains were from samples 
collected in internal medicine (n=2), pediatrics (n=9) and one outpatient. There were 
CTX-M (n=9) positive strains from pediatrics (n= 7), internal medicine (n=1) and one 
outpatient. Seven strains showed the presence of pAmpC genes in various 
combinations. 
 
Clade C clustered eight strains from urine (n=7) and blood (n=1) cultured from patients 
at internal medicine (n= 1), pediatrics (n= 6) and surgery (n= 1). The CTX-M positive 
strains were from pediatrics (n= 6).  Six strains were pAmpC positive with 13 blaAmpC 
genes in total. Clade D comprised of 12 strains; urine (n=11) and blood (n=1) from 
patients hospitalized in pediatrics (n= 9), internal medicine (n= 2) as well as one 
outpatient. The eight CTX-M positive strains were from pediatrics (n=6), internal 
medicine (n=1) and one outpatients.  Six strains showed the presence of a total of 13 
pAmpC genes.   
 
The clade E strains (n=11) were from urine (n=9) and blood (n=2) and were all CTX-M 
positive. These strains were from samples collected in patients admitted at internal 
medicine (n= 3), pediatrics (n= 6) and outpatients (n= 2). Five pAmpC genes were 
detected from 2 strains.  Clade F clustered 12 strains; urine (n=6) and blood (n=6) from 
samples collected in patients at pediatrics (n= 7), internal medicine (n= 4) and surgery 
(n= 1). Nine CTX-M positive strains were from the departments of pediatrics (n=5), 
internal medicine (n=3) and surgery. Six pAmpC genes were detected in 2 strains.  
 
The clade G strains (n=7) were from urine (n=2) and blood (n=5). Five strains were 
CTX-M positive. These strains were from samples collected in patients admitted at 
pediatrics (n= 4) and internal medicine (n= 3). The five CTX-M positive strains were 
from pediatric (n=3) and internal medicine (n=2). One strain was positive for two 
pAmpC genes. The clade H strains (n=3) were all urine isolates and the CTX-M 
positive strains (n=2) were from samples collected in patients at pediatrics and 





To our knowledge this is the first study describing the presence of plasmid-mediated 
AmpC- and/or ESBL-producing clinical isolates of E. coli in Mozambique. Recent 
literature reviews show that most African studies on the presence of ESBL-producing 
Enterobacteriaceae have been conducted in Northern and Eastern Africa, with a relative 
lack of data in Sub- Saharan Africa with a few exceptions [Mshana et al., 2013, Sangare 
et al., 2015, Sonda et al., 2016). There are very limited data from surveillance studies 
and a few clinical studies documenting the susceptibility pattern of common pathogens 
from human and animals. All studies underline the threat of antimicrobial resistance in 
general and ESBL-producing Enterobacteriaceae in particular. Moreover, several 
studies underline the free availability of antibiotics from private pharmacies and drug 
shops for self-medication before seeking medical service, as part of the complexity. The 
overall findings reveal a great variety in proportions of ESBL-producing 
Enterobacteriaceae between countries, underlining the importance of active surveillance 
studies and local data in order to guide antimicrobial therapy and infection control 
[Mshana et al., 2013, Sonda et al., 2016].   
 
The overall presence of plasmid-mediated AmpC- and/or ESBL-producing in clinical 
isolates of E. coli was (n=25/230; 10.8%) and (n=75/230; 32.6%), respectively. They 
were present in both urinary tract and blood culture isolates and with a higher 
prevalence in the latter and in urine samples from inpatients. CTX-Ms were the most 
dominant ESBL-type, with CTX-M 15 as the major subtype. Most of the blaCTX-M 
negative ESBL-positive strains were negative for blaTEM, but positive for blaSHV, 
indicating an SHV-ESBL-type. This is in accordance with the international situation 
[Paterson et al., 2009, Umaer and Sundsfjord 2011]. A 2010-11 survey in the United 
States showed that CTX-M type accounted for 85% of ESBL-producing E. coli strains 
[Laxminarayn et al., 2013]. 
 
 In China, CTX-M-type ESBLs accounted for more than 70% ESBL-producing E.coli 
over the past 10 years and CTX-M-14 was the most abundant genotype, although the 
detection rate of CTX-M-15 showed a continuously increasing trend in recent years [Li 
et al., 2012, Tian et al., 2012]. Moreover, a study in Sub-Saharan Africa of ESBL- 
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producing Enterobacteriaceae in stool samples in Mali, Niger and Cameroon showed 
that CTX-M was the dominant ESBL-type [Sangare et al., 2015].  
 
A total of 25/230 (11 %) of the strains expressed an AmpC phenotype and all contained 
pAmpC. Surprisingly, all strains contained two to three pAmpC genes. BlaFox was the 
most prevalent in our strains. These observations contrast the worldwide observations of 
blaCMY as the most prevalent pAmpC gene in E. coli populations [Jacoby 2009]. CMY-2 
has the broadest geographic spread among pAmpCs and is an important cause of 
extended beta-lactam resistance in E. coli as well as in nontyphoid Salmonella strains in 
many countries [Egorova et al., 2008]. The finding of multiple pAmpC-bla genes in 
single strains has recently been reported in a Tunisian study. A total of 11 out of 75 
pAmpC positive clinical strains of Enterobacteriaceae were shown to contain up to three 
different pAmpCs [Cherif et al., 2016].  In contrast to our study CMY-2 was the most 
common pAmpC-type in this strain collection.  Moreover, the combination of    MOX-, 
FOX- and CMY-2 type enzymes was dominant in their strains, in contrast to our strains 
that mostly contained MOX- and FOX-types in combination with DHA. 
 
ERIC-PCR has been a useful rapid method in various molecular epidemiological studies 
to describe the genetic relatedness in Enterobacteriaceae strain collections [Ranjbar et 
al. 2014].  Our ERIC-PCR results revealed an overall genetic diversity of ESBL- and/or 
pAmpC-positive E. coli strains at the Maputo Central Hospital. The results indicate that 
there is not a dominant clone of ESBL-/pAmpC positive E. coli. However, there are 
several clades with clonal relatedness indicating minor outbreaks between patients at 
specific departments. This notion is supported by the isolation of CTX-M-15 producing 
strains with similar resistance patterns from the Pediatric department linked in time 
within clade B (data not shown). 
 
The observation of multidrug resistant pAmpC- and/or ESBL-producing E. coli in a 
high proportion of clinical strains during a period of three months is a major concern. E. 
coli is the most prevalent cause of urinary tract infections and Gram-negative 
bacteremia. A large proportion of the ESBL-producing strains also expressed resistance 
to fluoroquinolones, aminoglycosides and trimethoprim-sulfamethoxazole. In such 
cases of MDR-septicemia the last resort antibiotics are carbapenems, piperacillin-
tazobactam, colistin or tigecycline. Those drugs are not easily available at Maputo 
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Central Hospital and in developing countries in general.  Thus, a significant amount of 
clinical strains of E. coli at the Maputo Central Hospital is in fact not treatable with the 
current available antibiotics.  
 
In conclusion, our study has shown: (i) a high proportion of ESBL- and/or pAmpC-
producing clinical isolates of E. coli from the urinary tract and blood cultures at the 
Central Hospital with CTX-Ms. (ii) CTX-Ms and FOX/MOX were the dominant ESBL- 
and pAmpC-types, respectively. (iii) All ESBL- and pAmpC-producing strains were 
MDR-strains only susceptible to antibiotics that are not easily available in the current 
location.  (iv) Studies of the genetic relatedness between ESBL- and/or pAmpC-
producing strains show genetic diversity and some clusters indicating within-hospital 
spread of strains. The overall findings strongly support the urgent need for accurate and 
rapid diagnostic services to guide correct treatment of serious life-threatening infections 
and improved infection control measurements. The findings have a probable transfer 
value to other hospitals in Mozambique as the Central hospital has reference functions 
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Figure 1: Dendrogram showing the cluster analysis of Escherichia coli isolated from blood and urine 
samples based on ERIC-PCR fingerprinting patterns using Jacquard index and UPGMA clustering. The 
scale at the top represents percentage similarity. Isolate columns:  identification number is given for each 
isolate with origin of the isolate in brackets: O = outpatient, P = paediatrics, M = medicine, S = surgery, 
U = urine, and B= blood. Amplification of CTX-M (and sequence type), SHV, TEM, CMY, DHA, MOX 
















































       Table1. Primer sequences for PCR amplification of ESBL and pAmpC genes  
Genes  Primers Sequence( 5' to 3') Annealing (ᵒC) Reference 
TEM 1 AAAATTCTTGAAGACG            60 [ Javier 2002] 
  2 TTACCAATGCTTAATCA     
CTX-M 1 GGTTAAAAAATCACTGCGTC            57 [ Javier 2002] 
  2 TTGGTGACGATTTTAGCCGC     
SHV 1 TTAACTCCCTGTTAGCCA            56 [ Javier 2002] 
  2 GATTTGCTGATTTCGCCC     
CMY 1 GAT TCC TTG GAC TCT TCA G             50 [ Sharma2010] 
  2 TAA AAC CAG GTT CCC AGA TAG C    
FOX 1 CAC CAC GAG AAT AAC CAT            50 [Sharma2010 ] 
  2 ATG TGG ACG CCT TGA ACT     
MOX 1 GCTGCTCAAGGAGCA CAG GAT            50 [ Sharma2010] 
 2 CACATTGACATAGGT GTG GTGC  
DHA 1 AACTTTCACAGGTGTGCT GGGT            50 [ Sharma2010] 
  2 CCGTACGCATACTGGCTT TGC     
 
 





























1001 Pediatric R R R R S R S S S S R 
1010 Medicine R R S R S R S S S S R 
1181 Pediatric R R R R R R S R S S R 
1568 Medicine R R S R R R S S S S R 
2560 Pediatric R R I R S R S R S R R 
3507 Medicine R R S R S R S S S S R 
5848 Medicine R R R R R R S S S R R 
6389 Medicine R R R R R R S S S S R 
7017 Pediatric R R R R R R S R I I R 
8810 Pediatric R R R R S R S R R R R 
9344 Pediatric R R R R R R S S I R R 
12900 Pediatric R R R R R R S S I I R 
12968 Medicine R R R R R R S R S R R 
12999 Pediatric R R R R R R S R R R R 
13308 Medicine R R R R R R S R R R R 
13311 Pediatric R R R R R R S S S S R 
13313 Medicine R R R R R R S R R R R 
       Abbrevations: S- susceptible; I- intermediate; R-resistant, CAZ- Ceftazidime; CTX- 
Cefotaxime; AMC- Amoxicilin Clavulanic acid;SXT- Trimethoprim-sulfamethoxazole; CIP- 
Ciprofloxacin; AMP- Ampicilin; MER-Meropenem; GEN- Gentamicin; FOX-  Cefoxitin; 











CTX AMC SXT CIP AMP MER NIT GEN FOX PTZ CRO 
980 Outpatient R R R R I R S S S S R R 
996 Outpatient R R R S S R S S R S R R 
1000 Outpatient R R R R R R S R R S S R 
1022 Pediatric R I R R I R S S R S S R 
1037 Pediatric R R R R R R S S R R R R 
1438 Pediatric R R R R S R S S R S S R 
1482 Medicine R R R R S R S S S I S R 
1620 Medicine R R R R R R S R S R I R 
2596 Pediatric R R R S S R S S R S S R 
3450 Pediatric R R I R S R S S R S S R 
3463 Pediatric R R R R S R S S R S S R 
3490 Pediatric R I R S S R S S S I R R 
5917 Pediatric R R R R R R S R R S I R 
4557 Pediatric R R R R S R S S S I S R 
4980 Medicine R R R R S R S S S R S R 
5100 Pediatric R R R R R R S S R S I R 
5102 Medicine R R S R S R S S S S S R 
5920 Pediatric R R R R R R S R S R I R 
6002 Pediatric I R R R R R S S S R S R 
6003 Pediatric R R R R R R S R R S R R 
6057 Pediatric R R R R S R S S S R R R 
6187 Pediatric R R R R R R S S S S I R 
6514 Pediatric I R R R R R S R S R S R 
6539 Pediatric R R R R R R S S R S R R 
6670 Outpatient R R R R R R S S R S S R 
6715 Medicine R R R R S R S S S I I R 
6818 Outpatient R R R R R R S R R S S S 
7421 Pediatric R R R R R R S S S S R R 
7922 Pediatric R R R R R R S I S S R R 
9479 Medicine R R R R R R S S S R R R 
9481 Pediatric R R R R S R S S S R R R 
10156 Pediatric R R R R R R S S R S R R 
10642 Outpatient R I I R S R S S S S S R 
10646 Pediatric R R R R R R S S S R S R 
10822 Outpatient R R R R S R S S S R S R 
10846 Pediatric R R R R S R S S R R R R 
10864 Pediatric R R R R R R S S R R R R 
10869 Pediatric R R R R R R S S S R R R 
11460 Pediatric R R R R R R S R R R S R 
11598 Surgery R R R R R R S R S R I R 
12394 Pediatric R R R R S R S R S S S R 
12958 Pediatric R R R R R R S R R R I R 
13036 Pediatric R R R R R R S S R R S R 
13088 Medicine R R R R R R S I R R R R 
13040 Pediatric R R R R R R S S S R R R 
13301 Pediatric R R R R R R S R R R S R 
13302 Pediatric R R R R S R S S S R I R 
13304 Pediatric R R R R R R S R S I R R 
13305 Pediatric R R R R R R S S R R I R 
13309 Pediatric R R R R R R S R I R R R 
13310 Pediatric R R R R R R S R R R R R 
13314 Pediatric R R R R R R S R S R R R 
13315 Medicine R R R R R R S R S R R R 
13316 Medicine R R R R R R S R S S S R 
13320 Surgery R R R R R R S R S R R R 
13335 Pediatric R R R R R R S R R R S R 
13313 Medicine R R R R R R S S R S R R 
10088 Medicine R R R R R R S S S S S R 
Abbreviotins: S- susceptible; I- intermediate; R-resistance; CAZ- Ceftazidime; CTX- Cefotaxime; 
AMC- Amoxacilin Clavulamic acid; SXT- Trimethoprim-sulfamethoxazole; CIP- Ciprofloxacin; 
AMP- Ampicilin; MER- Meropenem; NIT- Nitrofurantoin; GEN- Gentamicin; FOX- Cefoxitin; 





CHAPTER  3.  CONCLUSION 
 
3.1 Introduction 
Clinical isolates of E. coli (n=230) were obtained from urine and blood culture samples 
collected from in- and outpatient at Central Hospital of Maputo, Mozambique during  
mid- August to mid- November, 2015. Seventy-five (32.6 %) isolates shown to be 
resistant to cefotaxime and/ or ceftazidime were selected for further studies. The 
resistance mechanisms in these isolates towards third generation cephalosporins were 
investigated using pheno- genotypic methods. The genetic relatedness between strains 
was delineated.  
The following main conclusions emanated from the study with respect to the study 
objectives. 
Objective 1: Clinical isolates of E. coli (n=230) were identified using biochemical tests 
and examined by antimicrobial susceptibility testing (AST). 
Objective 2: Seventy-five (32.6 %) of the isolates were resistant to ceftazidime and/or 
cefotaxime and selected for further studies. 
Objective 3: The presence of increased AmpC- and/or ESBL-production was observed 
using specific double – disc synergy tests in isolates with reduced susceptibility to 
cefotaxime and/or ceftazidime. 
Objective 4: None isolates expressed reduced susceptibility to meropenem. Thus, no 
strains were further examined for carbapenemase activity. 
 
Objective 5: The ESBLs and pAmpCs at the Central Hospital of Maputo are mediated 
by CTX-M, SHV and FOX, MOX and CMY betalactamases, respectively. CTX-M-15 
is the dominant ESBL and FOX is the dominant pAmpC. 
 
Objective 6: These results will be important in the process of establishing empirical 








1. The strains were collected during a short period of time.  There seems to be a 
preference for sample collection at specific departments (Pediatrics) at the hospital. 
Thus, the overall prevalence of ESBL- and pAmpC-producing strains may be 
questioned.   
2. Limited resources precluded the final identification of some blaCTX-M and all blaSHV 
genotypes as well as more extensive comparative genetic analysis of strain relatedness. 
 
1.6 Recommendations 
 The study confirmed a relative high occurrence of ESBL- and pAmpC-
producing clinical strains of E. coli at the hospital. The strains are multidrug 
resistant.  The findings underline the importance of bacterial culture and 
susceptibility testing to be able to choose the correct antimicrobial treatment. 
Physicians must request bacteriological samplings for AST to ensure correct use 
of antibiotics. 
 The study found some genetic clusters of pAmpC- and/or ESBL-producing 
strains supporting strain transfer between departments and patients. This 
observation strongly supports the need for appropriate infection control 
measures within the hospital at all level. 
 The overall recommendation underline the urgent need for accurate and rapid 
diagnostic services to guide correct treatment of serious life-threatening 
infections and improved infection control measurements; 
 
1.7 Significance 
 This is the first antimicrobial resistance study conducted at the Central 
Hospital of Maputo confirming antimicrobial resistance as a serious health 
problem with the presence of multidrug resistant E. coli in all hospital 
departments. 
 Due to a very high occurrence of resistance to trimethoprim-sulfamethoxazole, 
ampicillin and cephalosporins it is important to review their use in relevant 
empiric treatment guidelines. 
 Considering that the Maputo Central Hospital is a referral hospital within the 
national health system in Mozambique, appropriate diagnostic services and 
infection control measures should be established in order to avoid the spread of 
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